<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=578690216770167&amp;ev=PageView&amp;noscript=1">
banner-img-2 mobile-banner-img

I am interested in booking my lumella

Introducing the rapid point-of-care
test in early detection of preeclampsia


Early & Effective Screening can help save lives

Testing period: Gestational age 13-37 weeks


The Lumella test estimates the concentration of Glycosylated Fibronectin, a new pregnancy specific biomarker to accurately assess the risk of preeclampsia

Measures glycosylated fibronectin (GlyFN)
Uses 5 μL finger prick blood sample
Results in 10 minutes

Early Symptoms of Preeclampsia are often too Ambiguous for Accurate Clinical Stratification

Clinical presentations often involve uncertain indications of hypertension and proteinuria
Less than 40% of women exhibit both hypertension and proteinuria before the development of overt preeclampsia
Preeclampsia progression is unpredictable and often complicated by adverse outcomes

The Lumella® GlyFN Test is intended as an aid in the diagnosis of women with suspected Preeclampsia.

Normal GlyFN 50-250μg/mL Correlated with normal pregnancy with high sensitivity of 98.2% and high Negative Predictive Value of 99.4%
Positive GlyFN 351-600 μg/mL Correlated with biochemical diagnosis of preeclampsia with 98% Positive Predictive Value
High Positive GlyFN >600 μg/mL Correlated with risk of severe preclampsia with 99% Positive Predictive Value